


WuXi AppTec expands California Site for Pharma R&D

10 December 2018 | News

WuXi AppTec's newly expanded facility will establish a centre of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including phase I GMP manufacturing.



WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations, has announced the expansion of its facilities in San Diego, California.

WuXi AppTec's newly expanded facility will establish a centre of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including phase I GMP manufacturing. The expansion will provide key elements of WuXi's small molecule capability and technology platform under one roof, further enhancing services to North American pharmaceutical and biotech industries. WuXi will also add extensively from the local talent base, further contributing to regional economic growth.

WuXi AppTec is a global capability and technology platform company with 27 sites around the world. WuXi AppTec has 1,700 employees in the U.S., and in addition to the San Diego site, it also has U.S. facilities and offices in Philadelphia (PA), St. Paul (MN), Atlanta (GA), Cranbury-Plainsboro (NJ), Cambridge (MA), and Austin (TX).